A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in.

Trial Profile

A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms DREAM
  • Most Recent Events

    • 01 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 08 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top